| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 44.92K | 84.18K | 0 | 290.56K | 52.01K |
| Revenue Growth % | - | - | 0.87% | -1% | - | -0.82% |
| Cost of Goods Sold | 0 | 3.5K | 2.59K | 81.03K | 2.82K | 22.73K |
| COGS % of Revenue | - | 0.08% | 0.03% | - | 0.01% | 0.44% |
| Gross Profit | 0 | 41.43K | 81.59K | -81.03K | 381.92K | 52.38K |
| Gross Margin % | - | 0.92% | 0.97% | - | 1.31% | 1.01% |
| Gross Profit Growth % | - | - | 0.97% | -1.99% | 5.71% | -0.86% |
| Operating Expenses | 480.22K | 891.67K | 937.15K | 1.62M | 1.58M | 1.87M |
| OpEx % of Revenue | - | 19.85% | 11.13% | - | 5.42% | 35.99% |
| Selling, General & Admin | 29.72K | 116.99K | 435.31K | 443.29K | 370.67K | 1.27M |
| SG&A % of Revenue | - | 2.6% | 5.17% | - | 1.28% | 24.34% |
| Research & Development | 323.98K | 784.2K | 806.45K | 1.13M | 1.2M | 1.43M |
| R&D % of Revenue | - | 17.46% | 9.58% | - | 4.15% | 27.48% |
| Other Operating Expenses | 126.51K | -9.52K | -304.61K | 41.26K | 0 | -823.1K |
| Operating Income | -480.22K | -1M | -1.4M | -1.7M | -3.2M | -2.63M |
| Operating Margin % | - | -22.33% | -16.61% | - | -11.01% | -50.5% |
| Operating Income Growth % | - | -1.09% | -0.39% | -0.21% | -0.89% | 0.18% |
| EBITDA | -382.99K | -782.14K | -1.15M | -1.4M | -3.12M | -2.53M |
| EBITDA Margin % | - | -17.41% | -13.72% | - | -10.74% | -48.74% |
| EBITDA Growth % | - | -1.04% | -0.48% | -0.22% | -1.22% | 0.19% |
| D&A (Non-Cash Add-back) | 97.22K | 220.99K | 243.92K | 293.32K | 77.47K | 91.59K |
| EBIT | -446.85K | -997.69K | -1.29M | -1.39M | -3.02M | -1.88M |
| Net Interest Income | -20.25K | 0 | -85.07K | -89.25K | 174.54K | 222.5K |
| Interest Income | 20.06K | 79.71K | 2.51K | 1.52K | 212.72K | 237.7K |
| Interest Expense | 0 | 79.71K | 87.58K | 90.77K | 38.18K | 15.2K |
| Other Income/Expense | -152.39K | -400.12K | -128.34K | -572.86K | 122.21K | 739.13K |
| Pretax Income | -632.61K | -1.4M | -1.53M | -2.27M | -3.08M | -1.89M |
| Pretax Margin % | - | -31.24% | -18.22% | - | -10.59% | -36.29% |
| Income Tax | 0 | 0 | 0 | 1.19K | 486 | 0 |
| Effective Tax Rate % | 1% | 1.05% | 1% | 1% | 1.02% | 1% |
| Net Income | -632.61K | -1.47M | -1.53M | -2.27M | -3.13M | -1.88M |
| Net Margin % | - | -32.66% | -18.22% | - | -10.78% | -36.21% |
| Net Income Growth % | - | -1.32% | -0.05% | -0.48% | -0.38% | 0.4% |
| Net Income (Continuing) | -632.61K | -1.47M | -1.53M | -2.27M | -3.13M | -1.89M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | -140 | -325 | -509 | -724 | 56.93K |
| EPS (Diluted) | -0.11 | -0.25 | -0.22 | -0.30 | -0.29 | -0.16 |
| EPS Growth % | - | -1.27% | 0.12% | -0.36% | 0.03% | 0.45% |
| EPS (Basic) | -0.08 | -0.25 | -0.22 | -0.30 | -0.29 | -0.16 |
| Diluted Shares Outstanding | 5.55M | 5.9M | 6.93M | 7.92M | 10.63M | 11.54M |
| Basic Shares Outstanding | 5.55M | 5.9M | 6.93M | 7.92M | 10.63M | 11.54M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 404.44K | 1.11M | 2.43M | 1.86M | 7.65M | 4.39M |
| Cash & Short-Term Investments | 338.29K | 703.2K | 1.87M | 1.18M | 6.82M | 3.64M |
| Cash Only | 275.83K | 670.27K | 1.86M | 1.18M | 6.82M | 3.64M |
| Short-Term Investments | 62.47K | 32.93K | 11.29K | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 13.75K |
| Days Sales Outstanding | - | - | - | - | - | 96.52 |
| Inventory | 35.45K | 182.05K | 320K | 430.17K | 514.32K | 614.2K |
| Days Inventory Outstanding | - | 19.01K | 45.1K | 1.94K | 66.48K | 9.86K |
| Other Current Assets | 16 | 196.8K | 136.54K | 218.61K | 199.92K | 97.3K |
| Total Non-Current Assets | 1.76M | 1.78M | 2.08M | 2.04M | 1.72M | 2.98M |
| Property, Plant & Equipment | 1.74M | 1.74M | 1.85M | 1.85M | 1.56M | 2.38M |
| Fixed Asset Turnover | - | 0.03x | 0.05x | - | 0.19x | 0.02x |
| Goodwill | 264 | 269 | 263 | 265 | 269 | 260 |
| Intangible Assets | 26.52K | 33.99K | 23.48K | 13.78K | 9.14K | 67.87K |
| Long-Term Investments | 0 | 0 | 202.4K | 178.75K | 147.82K | 161.78K |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 366.11K |
| Total Assets | 2.17M | 2.89M | 4.51M | 3.9M | 9.37M | 7.37M |
| Asset Turnover | - | 0.02x | 0.02x | - | 0.03x | 0.01x |
| Asset Growth % | - | 0.33% | 0.56% | -0.13% | 1.4% | -0.21% |
| Total Current Liabilities | 277.46K | 2.06M | 2.18M | 3.11M | 543.28K | 444.18K |
| Accounts Payable | 9.18K | 14.32K | 34.29K | 10.92K | 18.65K | 28.29K |
| Days Payables Outstanding | - | 1.5K | 4.83K | 49.19 | 2.41K | 454.17 |
| Short-Term Debt | 26.61K | 1.79M | 2M | 2.79M | 25.71K | 27.57K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 210.84K | 40.2K | 29.67K | 126.69K | 155.68K | 115.97K |
| Current Ratio | 1.46x | 0.54x | 1.12x | 0.60x | 14.08x | 9.89x |
| Quick Ratio | 1.33x | 0.45x | 0.97x | 0.46x | 13.14x | 8.51x |
| Cash Conversion Cycle | - | - | - | - | - | 9.5K |
| Total Non-Current Liabilities | 464.85K | 465.04K | 411.1K | 355.04K | 309K | 305.58K |
| Long-Term Debt | 444.5K | 447.22K | 399.74K | 350.03K | 309K | 288.72K |
| Capital Lease Obligations | 20.34K | 17.82K | 11.36K | 5.01K | 0 | 16.86K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 742.31K | 2.53M | 2.59M | 3.46M | 852.28K | 749.76K |
| Total Debt | 496.96K | 2.26M | 2.42M | 3.15M | 339.5K | 339.2K |
| Net Debt | 221.14K | 1.59M | 553.08K | 1.97M | -6.48M | -3.3M |
| Debt / Equity | 0.35x | 6.27x | 1.26x | 7.20x | 0.04x | 0.05x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | - | -12.58x | -15.97x | -18.69x | -83.79x | -172.79x |
| Total Equity | 1.43M | 360.23K | 1.92M | 437.73K | 8.52M | 6.62M |
| Equity Growth % | - | -0.75% | 4.33% | -0.77% | 18.47% | -0.22% |
| Book Value per Share | 0.26 | 0.06 | 0.28 | 0.06 | 0.80 | 0.57 |
| Total Shareholders' Equity | 1.43M | 360.37K | 1.92M | 438.24K | 8.52M | 6.57M |
| Common Stock | 2.23M | 2.65M | 4.86M | 6.65M | 17.97M | 17.42M |
| Retained Earnings | -803.25K | -2.28M | -3.76M | -6.12M | -9.34M | -10.87M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.29K | -6.32K | 823.34K | -95.18K | -108.72K | 14.81K |
| Minority Interest | 0 | -140 | -325 | -509 | -724 | 56.93K |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -471.85K | -692.31K | -1.27M | -1.1M | -2.59M | -1.69M |
| Operating CF Margin % | - | -15.41% | -15.09% | - | -8.92% | -32.59% |
| Operating CF Growth % | - | -0.47% | -0.83% | 0.13% | -1.34% | 0.35% |
| Net Income | -632.61K | -1.47M | -1.52M | -2.34M | -3.13M | -1.84M |
| Depreciation & Amortization | 132K | 221.49K | 244.59K | 293.31K | 288.82K | 245.56K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 57.09K | 674.29K | 327.66K | 1.05M | 256.37K | -39.47K |
| Working Capital Changes | -28.32K | -122.69K | -321.14K | -108.38K | -3.98K | -57.91K |
| Change in Receivables | 7.12K | -122.69K | -321.14K | -108.38K | -3.98K | -57.91K |
| Change in Inventory | -26.11K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -872.98K | -371.94K | -610.72K | -353.37K | -2.11M | 494.59K |
| Capital Expenditures | -872.98K | -185.29K | -431.8K | -353.74K | -44.17K | -1.03M |
| CapEx % of Revenue | - | 4.12% | 5.13% | - | 0.15% | 19.71% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | -6.94K | 640 | 11 | 772 | 1.52M |
| Cash from Financing | 887.24K | 1.44M | 3.09M | 793.25K | 8.16M | -33.36K |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 909.23K | 1.09M | 161.63K | -252.12K | -222.82K | -716 |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -1.34M | -828.43K | -1.7M | -1.4M | -2.72M | -3.01M |
| FCF Margin % | - | -18.44% | -20.22% | - | -9.36% | -57.87% |
| FCF Growth % | - | 0.38% | -1.05% | 0.18% | -0.95% | -0.11% |
| FCF per Share | -0.24 | -0.14 | -0.25 | -0.18 | -0.26 | -0.26 |
| FCF Conversion (FCF/Net Income) | 0.75x | 0.47x | 0.83x | 0.49x | 0.83x | 0.90x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -44.36% | -164.26% | -134.45% | -192.48% | -69.92% | -24.87% |
| Return on Invested Capital (ROIC) | - | -41.86% | -47.45% | -52.12% | -107.78% | -73.42% |
| Gross Margin | - | 92.22% | 96.92% | - | 131.44% | 100.72% |
| Net Margin | - | -3266.07% | -1822.31% | - | -1077.85% | -3621.15% |
| Debt / Equity | 0.35x | 6.27x | 1.26x | 7.20x | 0.04x | 0.05x |
| Interest Coverage | - | -12.58x | -15.97x | -18.69x | -83.79x | -172.79x |
| FCF Conversion | 0.75x | 0.47x | 0.83x | 0.49x | 0.83x | 0.90x |
| Revenue Growth | - | - | 87.38% | -100% | - | -82.1% |
CytoMed Therapeutics Limited (GDTC) reported $0.4M in revenue for fiscal year 2024.
CytoMed Therapeutics Limited (GDTC) saw revenue decline by 82.1% over the past year.
CytoMed Therapeutics Limited (GDTC) reported a net loss of $3.4M for fiscal year 2024.
CytoMed Therapeutics Limited (GDTC) has a return on equity (ROE) of -24.9%. Negative ROE indicates the company is unprofitable.
CytoMed Therapeutics Limited (GDTC) had negative free cash flow of $3.0M in fiscal year 2024, likely due to heavy capital investments.